For research use only. Not for therapeutic Use.
Brazikumab（Cat No.:I042152）is a monoclonal antibody that targets the interleukin-23 (IL-23) pathway, which plays a central role in the immune response and inflammation. By inhibiting IL-23, Brazikumab aims to reduce the activity of immune cells involved in chronic inflammatory conditions. It is primarily being studied for the treatment of autoimmune diseases like Crohn’s disease and ulcerative colitis. Clinical trials have shown that Brazikumab effectively reduces inflammation and symptoms associated with these conditions. Ongoing research continues to assess its safety, effectiveness, and potential for broader therapeutic uses.
| Catalog Number | I042152 |
| CAS Number | 1610353-18-8 |
| Purity | ≥95% |
